Infographics

  1. CDMO Preference For Small Molecule Drug Substance 4/13/2022

    ISR asked API outsourcers which CDMOs they are currently working with and which CDMO they prefer to use for all small molecule drug substance manufacturing. Delve into the data which showed that Cambrex, Patheon, Lonza, STA Pharma and Pfizer CentreOne are the preferred CDMOs among roughly one-third of their current customers.

  2. Preference Among Users: New And Emerging Biopharma 4/13/2022

    ISR asked new and emerging biopharma respondents which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer.

  3. Biologic Drug Product Outsourcing Drivers By Company Size 2/14/2022

    The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (71%) while sponsors from non-large pharma use CMOs for all manufacturing needs (66%).

  4. Small Molecule Drug Substance Pandemic Complications 1/14/2022

    Over the past two years, ISR has asked respondents to its annual small molecule drug substance benchmarking surveys whether they encountered pandemic related complications with their outsourced manufacturing. The data show it was slightly more common for small molecule API outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020.

  5. Biologic Sterile Injectable Outsourcing Volume 11/15/2021

    On average, respondents have 4.5 marketed biologic products, of which 65% of drug product manufacturing is outsourced. Respondents use an average of 3.3 CDMOs. 

  6. Using The Same CDMO For Development And Commercial Manufacturing 9/18/2021

    Discover why 80% of survey respondents indicated it is at least moderately important to use the same CDMO for both development activities and commercial manufacturing.

  7. Reasons CDMOs Lose Oral Dose Manufacturing Bids 11/13/2020

    In Q2, 2019, ISR asked 101 respondents who outsource oral dose drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 30% of respondents’ votes.

  8. Reasons CDMOs Lose Sterile Injectable Manufacturing Bids 11/13/2020

    In Q2 2019, ISR asked 101 respondents who outsource sterile injectable drug product manufacturing what is the main reason a CDMO may lose the bid for an outsourced manufacturing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 25% of respondents’ votes..

  9. Reasons CDMOs Lose Bioprocessing Bids 9/15/2020

    In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 32% of respondents’ votes.

  10. Top Five Oral Dosage Forms By Portfolio Composition 9/12/2019

    The top five oral dosage forms account for more than half of products in oral dose portfolios and are: tablets, capsules, controlled release tablets, controlled release capsules, and immediate release tablets.